FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Young Caroline			2. Issuer Name and Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS INC [CPIX]		tionship of Reporting Perso all applicable) Director Officer (give title	10% Owner Other (specify
(Last) 2525 WEST EN SUITE 950	(First) D AVENUE	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 08/16/2022		below)	below)
(Street) NASHVILLE (City)	TN (State)	37203 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	ridual or Joint/Group Filing Form filed by One Repor Form filed by More than Person	rting Person

(Street) NASHVILLE TN	37203						X	Form filed by On Form filed by Mo Person		
(City) (State)	(Zip)						<u> </u>			
1. Title of Security (Instr. 3)	able I - Non-Derivative S 2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date,	3.		4. Securities Disposed O 5)	s Acquired	d (A) or	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V		Amount	(A) or (D)	Price			
Common Stock	08/16/2022		P		20(1)	A	\$2.35	17,702	D	
Common Stock	08/17/2022		P		20(1)	A	\$2.31	17,722	D	
Common Stock	08/18/2022		P		20(1)	A	\$2.23	17,742	D	
Common Stock	08/19/2022		P		20(1)	A	\$2.35	17,762	D	
Common Stock	08/22/2022		P		20(1)	A	\$2.51	17,782	D	
Common Stock	08/23/2022		P		20(1)	A	\$2.59	17,802	D	
Common Stock	08/24/2022		P		20(1)	A	\$2.59	17,822	D	
Common Stock	08/25/2022		P		20(1)	A	\$2.62	17,842	D	
Common Stock	08/26/2022		P		20(1)	A	\$2.55	17,862	D	
Common Stock	08/29/2022		P		22(1)	A	\$2.44	17,884	D	
Common Stock	08/30/2022		P		22(1)	A	\$2.38	17,906	D	
Common Stock	08/31/2022		P		22(1)	A	\$2.36	17,928	D	
Common Stock	09/01/2022		P		22(1)	A	\$2.39	17,950	D	
Common Stock	09/02/2022		P		22(1)	A	\$2.42	17,972	D	
Common Stock	09/06/2022		P		22(1)	A	\$2.15	17,994	D	
Common Stock	09/07/2022		P		22(1)	A	\$2.24	18,016	D	
Common Stock	09/08/2022		P		22(1)	A	\$2.22	18,038	D	
Common Stock	09/09/2022		P		20(1)	A	\$2.21	18,058	D	
Common Stock	09/12/2022		P		22(1)	A	\$2.46	18,080	D	
Common Stock	09/13/2022		P		22(1)	A	\$2.45	18,102	D	
Common Stock	09/14/2022		P		22(1)	A	\$2.51	18,124	D	
Common Stock	09/15/2022		P		22(1)	A	\$2.47	18,146	D	
Common Stock	09/16/2022		P		22(1)	A	\$2.49	18,168	D	
Common Stock	09/19/2022		P		20(1)	A	\$2.56	18,188	D	
Common Stock	09/20/2022		P		20(1)	A	\$2.54	18,208	D	
Common Stock	09/21/2022		P		20(1)	A	\$2.59	18,228	D	
Common Stock	09/22/2022		P		20(1)	A	\$2.51	18,248	D	
Common Stock	09/23/2022		P		20(1)	A	\$2.55	18,268	D	
Common Stock	09/26/2022		P		20(1)	A	\$2.49	18,288	D	
Common Stock	09/27/2022		P		20(1)	Α	\$2.57	18,308	D	İ

	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)														
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year) f ive y 3. Transaction Execution Date, if any (Month/Day/Year) (Month/Day/Year) 4. Transaction Code (Instr. 8)		of Deriv Secu Acqu (A) o Dispo of (D (Inst	Derivative (Month/Day/Year) Securities Acquired (A) or			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

1. The purchases reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2022.

Remarks:

Caroline Young by /s/ John Hamm as attorney-in-fact

09/30/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.